Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Madrigal Pharmaceuticals, Inc. MDGL

Healthcare — Biotechnology

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total sells
81.48
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell — 3 4 9 — 6 — 2 1 1 1 1
Insider Ownership
26.16%

Capital & Financial Ratios

Market Cap
12,350.00
Revenue
1,283.94
Net Income
(325.09)
Free Cash Flow
(206.28)
Net Debt
(498.11)
Current Ratio
3.20
Debt/Equity
0.65
P/E ratio
0.00
P/S ratio
12.07
P/B ratio
29.58
Past 5Y EPS Growth
(32.06%)
This Y EPS Growth
51.27%
Next Y EPS Growth
204.62%
Next 5Y EPS Growth
0.00%
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2025 ‡‡‡
2024 ‡‡‡
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
2020 ‡‡‡
2019 ‡‡‡
2017 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 634.13 931.25 988.65 838.91
Receivables — 53.82 134.48 192.31
Inventory — 34.07 74.84 99.39
Other — — — —
637.28 1,032.93 1,245.77 1,199.18
2023 2024 2025 Q'26
Payables 28.04 43.60 48.88 34.51
ST’ Debt — — — —
Other — — — —
118.55 169.28 310.29 374.20
in millions of $

Compound Annual Growth

10y 5y 3y
Sales — — ‡‡‡‡‡
Cash Flow ‡‡‡ ‡‡‡ ‡‡‡
Earnings ‡‡‡ ‡‡‡ ‡‡‡
Book Value ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 311.34 364.25 — —
—
’25 137.25 212.80 287.27 321.08
958.40
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 (167.43) 23.33 — —
—
’25 (88.89) (47.05) 79.85 (133.46)
(189.55)
’24 (149.16) (134.94) (66.98) (104.49)
(455.57)
’23 (84.07) (75.31) (84.92) (79.93)
(324.23)
’22 (49.91) (57.36) (59.07) (58.51)
(224.86)
’21 (43.43) (46.88) (45.56) (48.05)
(183.92)
’20 (30.51) (24.26) (47.85) (54.95)
(157.56)
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 (171.28) 19.08 — —
—
’25 (88.89) (47.05) 75.99 (133.07)
(193.02)
’24 (149.51) (140.08) (67.76) (104.68)
(462.03)
’23 (84.10) (75.38) (85.26) (80.97)
(325.71)
’22 (49.96) (57.46) (59.10) (58.54)
(225.07)
’21 (43.47) (46.88) (45.61) (48.16)
(184.13)
’20 (30.82) (24.26) (47.85) (54.96)
(157.89)
in millions of $

EPS

Mar Jun Sep Dec Year
’26 (3.25) (1.99) — —
—
’25 (3.32) (1.90) (5.08) (2.57)
(12.85)
’24 (7.38) (7.10) (4.92) (2.71)
(21.90)
’23 (4.23) (4.69) (5.34) (5.68)
(19.99)
’22 (3.36) (4.14) (4.75) (4.98)
(17.23)
’21 (3.32) (3.72) (3.79) (3.78)
(14.63)
’20 (2.34) (3.18) (3.75) (3.82)
(13.09)

Target Price Range

High
‡‡‡‡‡
‡‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡‡

Recommendation Rating

1.2
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 52.33 119.76 168.25 265.00 — — —
Low Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 315.45 322.67 368.29 615.00 — — —
High Price
‡‡‡ ‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ 92 376 528 915 — — —
Employees
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00 0.00 0.34 1.05 — — —
Revenue/Emp
— — — — — — — — 180.13 958.40 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00% — 96.54% 94.14% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (295.35) (373.63) (465.89) (288.28) — — —
EBT
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00% 0.00% (258.64%) (30.08%) ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (295.35) (373.63) (465.89) (288.28) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.26 2.94 2.79 6.32 — — —
Depreciation
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00 0.00 8.47 42.72 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (17.23) (19.99) (21.90) (12.85) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (13.12) (17.35) (21.42) (8.45) ‡‡‡‡‡ — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.01) (0.08) (0.30) (0.15) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (13.13) (17.43) (21.72) (8.60) — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 11.52 21.69 35.46 26.87 ‡‡‡‡ — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 17.14 18.69 21.27 22.43 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
— — — — — — — — 0.00 0.00 ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡
PE Ratio
— — — — — — — — 0.00 13.63 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
— — — — — — — — 8.70 21.68 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
— — — — — — — — 0.00 12.95 ‡‡‡ ‡‡‡‡ ‡‡‡
EV/Sales
— — — — — — — — (12.45) (64.00) — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (224.86) (324.23) (455.57) (189.55) ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.22) (1.48) (6.46) (3.47) ‡‡‡‡‡ ‡‡‡‡‡ —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (225.07) (325.71) (462.03) (193.02) ‡‡‡‡‡ — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 245.48 518.73 863.65 935.48 — — —
Working Cap'
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 49.89 115.48 117.57 339.88 — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (308.88) (518.65) (813.68) (648.77) — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 197.39 405.33 754.38 602.69 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (92.89%) (74.49%) (55.37%) (25.05%) — — —
ROA
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00% 0.00% 0.00% 0.00% — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (150.12%) (123.98%) (80.35%) (42.49%) — — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Madrigal Pharmaceuticals (MDGL) has reached a transformative milestone with FDA approval of its flagship drug Rezdiffra (resmetirom) in March 2024, marking the first therapy for metabolic dysfunction-associated steatohepatitis (MASH). After years as a cash-burning biotech with a volatile stock tied to clinical milestones—from $5 lows in 2016 to $368 highs post-approval—the company generated its debut $180 million in revenue in 2024. This shift from deep losses and negative free cash flow to a commercial powerhouse is fueled by aggressive hiring (headcount up 41% to 528), elite 96.5% gross margins, and a fortified balance sheet with $864 million in working capital.

Explosive growth lies ahead: revenue per share is projected to surge 394% to $41.82 in 2025, reaching $94.32 by 2027 amid $2 billion-plus potential peak sales, flipping EBT positive and delivering $15.24 EPS with profitability by 2027. Insider signals mix optimism—a director’s $62 million buy in August 2025—with profit-taking sells, while analysts forecast 15-108% upside, with forward multiples compressing to under 1x sales. Rezdiffra’s Phase 3 success positions MDGL as MASH pioneer, but execution risks like payer adoption and GLP-1 competition loom.

This biotech survivor’s arc—from an 8-person team bleeding losses to a revenue leader—screams asymmetric upside for patient investors, with Q1 2026 uptake as the key catalyst.

Read full commentary →

Madrigal Pharmaceuticals, Inc. (MDGL) Latest News

News by impact score

Fine-tune

25 Aug

4 www.fool.com, 12:20 PM
Madrigal Pharmaceuticals stock requires positive phase 3 data for resmetirom, FDA approval, and strong commercial uptake in NASH to drive meaningful gains and shift investor sentiment. Successful regulatory approval and launch would represent major milestones capable of substantially altering the company's trajectory and valuation.

15 Aug

4 www.marketbeat.com, 5:01 AM
Madrigal’s Rezdiffra reaches $1.3B annualized run rate as the company advances its MASH pipeline. Rezdiffra's $1.3B run rate and pipeline expansion indicate major commercial traction and growth outlook for Madrigal.

31 Jul

3 , 2:09 PM
Madrigal Pharmaceuticals beat earnings estimates. Questions remain whether the stock trades below fair value. Earnings beat signals improved financial results but leaves valuation open to further market assessment.

3 , 11:34 AM
MDGL stock fell after Q2 earnings beat, with MASH drug driving year-over-year top-line revenue growth. Q2 beat and MASH drug revenue growth point to noticeable but limited effects on financial results and sentiment.

30 Jul

4 www.marketbeat.com, 2:04 PM
Madrigal Pharmaceuticals reported Q2 financial results and operational updates during its earnings call, including pipeline developments and forward guidance. Q2 earnings results and guidance directly affect investor views on financial trajectory and strategy.

3 , 8:35 AM
Madrigal Pharmaceuticals reported Q2 loss while beating revenue estimates. Quarterly earnings results affect near-term financial perception and investor views on operations.

3 , 7:00 AM
Madrigal Pharmaceuticals reported second-quarter 2026 financial results and provided corporate updates. Quarterly results releases typically produce moderate short-term market reaction without shifting long-term company trajectory.

13 Jul

4 stocktwits.com, 7:47 PM
Retail traders focus on MDGL stock amid M&A speculation and pipeline moves. M&A speculation and pipeline moves can significantly alter company trajectory and investor sentiment.

4 , 8:00 AM
Madrigal Pharmaceuticals obtained three new patents for resmetirom, strengthening its intellectual property portfolio. New patents extend market exclusivity for resmetirom and reinforce Madrigal's competitive position.

1 Jul

4 , 9:29 PM
Madrigal Pharmaceuticals and Ribo reached the first major milestone advancing novel siRNA therapies for MASH. Major milestone in siRNA therapies for MASH expands Madrigal pipeline and strengthens competitive positioning.

4 , 9:19 PM
Madrigal Pharmaceuticals and Ribo achieved the first major milestone advancing novel siRNA therapies for MASH. Milestone in siRNA MASH therapies expands Madrigal pipeline and competitive positioning.

29 Jun

4 www.pharmavoice.com, 5:00 AM
Three late-stage MASH drugs are advancing as potential competitors to Madrigal Pharmaceuticals' Rezdiffra. Potential rival drugs threaten Rezdiffra's market dominance for Madrigal.

9 Jun

4 Simply Wall St., 2:14 AM
New Rezdiffra cardiometabolic data release may change the bull case for Madrigal Pharmaceuticals (MDGL). New Rezdiffra data release carries potential to significantly alter Madrigal market trajectory and investor sentiment.

4 Jun

4 Insider Monkey, 5:07 AM
Madrigal Pharmaceuticals presented data at the EASL Congress showing Rezdiffra’s cardiometabolic benefits for MASH patients. Positive Rezdiffra data at major congress strengthens Madrigal’s MASH positioning and investor outlook.

27 May

4 GlobeNewswire, 8:00 AM
Madrigal Pharmaceuticals presented clinical data showing Rezdiffra reduced markers of cardiovascular and liver-related risk in MASH patients. Positive Rezdiffra efficacy data in MASH directly strengthens Madrigal's commercial outlook and investor positioning.

20 May

3 GlobeNewswire, 8:00 AM
Madrigal Pharmaceuticals will present new data from its MASH program at EASL 2026 showing Rezdiffra effects on cardiovascular and portal hypertension risk markers. Upcoming conference data on Rezdiffra benefits may lift short-term sentiment and support valuation without immediate fundamental shifts.

10 May

4 Simply Wall St., 3:08 PM
Madrigal Pharmaceuticals (MDGL) reported strong Q1 2026 earnings and robust Rezdiffra sales growth, triggering a fresh valuation assessment. Strong Q1 2026 earnings and Rezdiffra sales growth represent major positive financial momentum likely to enhance MDGL's trajectory and investor sentiment.

7 May

4 Zacks, 11:35 AM
Madrigal Pharmaceuticals beat Q1 earnings estimates, driven by strong sales of its MASH drug, boosting top-line revenue and sending shares higher. Earnings beat fueled by MASH drug sales confirms commercial success and accelerates growth trajectory.

6 May

4 www.marketbeat.com, 3:44 PM
Madrigal Pharmaceuticals (MDGL) released highlights from its Q1 earnings call, covering financial results, operational updates, and forward guidance. Q1 earnings call highlights provide critical insights into financial health, pipeline progress, and strategic outlook, poised to significantly sway MDGL's stock performance and investor confidence.

4 app.moby.co, 12:57 PM
Madrigal Pharmaceuticals, Inc. (MDGL) released Q1 2026 earnings call summary covering financial results, operational highlights, pipeline updates, and forward guidance. Q1 2026 earnings call summary details financial performance and strategic outlook, poised to significantly sway MDGL's market trajectory and investor confidence.

4 transcript www.fool.com, 12:15 PM
Madrigal Pharmaceuticals (MDGL) released Q1 2026 earnings call transcript covering financial results, Rezdiffra sales growth, commercialization progress, pipeline updates, and reaffirmed 2026 revenue guidance of $1.0 to $1.1 billion. Q1 2026 earnings highlight strong Rezdiffra revenue ramp-up and positive guidance, significantly boosting MDGL's growth trajectory and investor confidence.

4 investorshub.advfn.com, 10:46 AM
Madrigal Pharmaceuticals (MDGL) reinforces its MASH strategy through accelerating Rezdiffra sales growth and pipeline expansion. Rezdiffra sales growth and pipeline expansion represent major strategic advancements that could significantly enhance MDGL's market position and investor sentiment in the MASH space.

4 GlobeNewswire, 7:00 AM
Madrigal Pharmaceuticals reported first-quarter 2026 financial results and provided corporate updates. Quarterly financial results and corporate updates signal major shifts in performance, pipeline progress, and strategy that can significantly sway stock price and investor confidence.

4 www.pharmaceutical-technology.com, 6:29 AM
Arrowhead Pharmaceuticals and Madrigal Pharmaceuticals signed a global licensing agreement granting Madrigal exclusive rights to develop and commercialize an investigational RNAi therapeutic targeting MASH, with Arrowhead receiving upfront payments, milestones, and royalties. Global licensing of a novel RNAi therapy for MASH significantly expands Madrigal's pipeline, complements its approved resmetirom, and enhances competitive positioning in a high-value indication.

3 Zacks, 8:25 AM
Madrigal Pharmaceuticals (MDGL) reported a Q1 net loss but beat revenue estimates. Q1 revenue beat despite loss moderately affects financial performance and investor sentiment.

5 May

5 www.pharmaceutical-technology.com, 11:53 AM
Madrigal Pharmaceuticals agrees to pay $1 billion for Arrowhead Pharmaceuticals' siRNA asset targeting MASH. The $1 billion acquisition of Arrowhead's siRNA MASH asset fundamentally bolsters Madrigal's pipeline and competitive position in the high-stakes MASH market.

4 Simply Wall St., 11:15 PM
Madrigal Pharmaceuticals (MDGL) licenses ARO-PNPLA3 from Arrowhead Pharmaceuticals, sparking debate on reshaping its MASH strategy amid competition and resmetirom approval. ARO-PNPLA3 license deal adds novel PNPLA3-targeting asset to MDGL's MASH pipeline, enabling strategic diversification and bolstering long-term competitive positioning.

4 GlobeNewswire, 8:00 AM
Madrigal Pharmaceuticals adds clinical-stage siRNA asset targeting PNPLA3 to its MASH pipeline. Pipeline expansion with clinical-stage siRNA targeting PNPLA3 strengthens Madrigal's position in the competitive MASH market.

4 Business Wire, 8:00 AM
Arrowhead Pharmaceuticals licenses its clinical-stage MASH program targeting PNPLA3 to Madrigal Pharmaceuticals, Inc. (MDGL). Licensing a clinical MASH program targeting PNPLA3 bolsters Madrigal's pipeline in its core therapeutic area, potentially accelerating growth and improving competitive positioning.

29 Apr

3 , 10:00 AM
Madrigal Pharmaceuticals (MDGL) is expected to surpass Q1 earnings estimates, driven by strong analyst consensus and key metrics to watch ahead of the release. Earnings beat expectations can moderately impact financial performance and short-term investor sentiment.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us